Advertisement

Pituitary

, 12:285 | Cite as

Efficacy of long-term lanreotide treatment in patients with acromegaly

  • Yoel Toledano
  • Liat Rot
  • Yona Greenman
  • Sophia Orlovsky
  • Yulia Pauker
  • David Olchovsky
  • Achia Eliash
  • Orit Bardicef
  • Ofa Makhoul
  • Gloria Tsvetov
  • Michal Gershinsky
  • Odile Cohen-Ouaqnine
  • Rosane Ness-Abramof
  • Zaina Adnan
  • Jacob Ilany
  • Hadassah Guttmann
  • Mazal Sapir
  • Carlos Benbassat
  • Ilan Shimon
Article

Abstract

We investigated the effectiveness of lanreotide for the treatment of active acromegaly in a retrospectively multicenter case series including 53 patients (24 male, 29 female; mean age at diagnosis, 49.5 ± 13.9 years) with acromegaly treated with lanreotide in nine different centers. Mean tumor diameter was 20 ± 13 mm; mean basal levels of growth hormone (GH) and insulin-like growth factor I (IGF-I) were 21.3 ± 26.3 and 579 ± 177 μg/l, respectively. The primary mode of treatment was surgery in 70% of patients. Twenty-nine patients received only lanreotide (Prolonged Release, Autogel), whereas 24 subjects were also treated with octreotide at another treatment stage. Primary therapy with lanreotide was administered in five patients. Maximal monthly dose of lanreotide Autogel (n = 44) was 60 mg in 45%, 90 mg in 26%, 120 mg in 21% and 180 mg in 8%. During 36 months of lanreotide treatment, mean IGF-I levels decreased from 443 ± 238 to 276 ± 147 μg/l (< 0.001), and mean GH levels, from 5.2 ± 6.4 to 3.2 ± 3.0 μg/l (P < 0.001). IGF-I levels normalized in 51% of patients and decreased by >50% towards normal in 32%; the normalization rate was higher in women (65%) than men (33%, P = 0.04). Safe random GH levels (≤2 μg/l) were achieved in 49% of patients. Both IGF-I normalization and safe GH levels were reached in 32% of the cohort. Lanreotide is an effective treatment for active acromegaly. Female sex was associated with higher rates of IGF-I normalization.

Keywords

Acromegaly Lanreotide Octreotide Pituitary adenoma Somatostatin 

Notes

Acknowledgments

This study was partially supported by a grant from Medison Pharma, Israel. We thank Ms. Gloria Ginzach for her assistance in the preparation of this manuscript.

References

  1. 1.
    Holdaway IM, Rajasoorya RC, Gamble GD (2004) Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 89:667–674. doi: 10.1210/jc.2003-031199 CrossRefPubMedGoogle Scholar
  2. 2.
    Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L, Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H, Nuutila P, Salmela P, Salmi J, Stenman UH, Viikari J, Voutilainen E (2005) A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab 90:4081–4086. doi: 10.1210/jc.2004-1381 CrossRefPubMedGoogle Scholar
  3. 3.
    Rajasoorya C, Holdaway IM, Wrightson P, Scott DJ, Ibbertson HK (1994) Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 41:95–102. doi: 10.1111/j.1365-2265.1994.tb03789.x CrossRefGoogle Scholar
  4. 4.
    Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F (2004) Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 89:2789–2796. doi: 10.1210/jc.2003-032041 CrossRefPubMedGoogle Scholar
  5. 5.
    Swearingen B, Barker FGII, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT (1998) Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 83:3419–3426. doi: 10.1210/jc.83.10.3419 CrossRefPubMedGoogle Scholar
  6. 6.
    Melmed S (2006) Acromegaly. N Engl J Med 355:2558–2573. doi: 10.1056/NEJMra062453 CrossRefPubMedGoogle Scholar
  7. 7.
    Heron I, Thomas F, Dero M, Gancel A, Ruiz JM, Schatz B, Kuhn JM (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J Clin Endocrinol Metab 76:721–727. doi: 10.1210/jc.76.3.721 CrossRefPubMedGoogle Scholar
  8. 8.
    Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Lauberg P, Pico AH, Valimaki M, Zgliczynsk W (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 87:99–104. doi: 10.1210/jc.87.1.99 CrossRefPubMedGoogle Scholar
  9. 9.
    Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, Lamberts SW, Marbach P, Orskov H, Pagani G, Sheppard M, Simionescu L (1996) Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism 45:67–71. doi: 10.1016/S0026-0495(96)90087-6 CrossRefPubMedGoogle Scholar
  10. 10.
    Freda PU (2002) Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87:3013–3018. doi: 10.1210/jc.87.7.3013 CrossRefPubMedGoogle Scholar
  11. 11.
    Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf) 64:209–214. doi: 10.1111/j.1365-2265.2006.02450.x CrossRefGoogle Scholar
  12. 12.
    Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A (2002) Acromegaly treatment consensus workshop participants. Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054–4058. doi: 10.1210/jc.2002-011841 CrossRefPubMedGoogle Scholar
  13. 13.
    Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526–529. doi: 10.1210/jc.85.2.526 CrossRefPubMedGoogle Scholar
  14. 14.
    Ronchi CL, Varca V, Giavoli C, Epaminonda P, Beck-Peccoz P, Spada A, Arosio M (2005) Long-term evaluation of postoperative acromegalic patients in remission with previous and newly proposed criteria. J Clin Endocrinol Metab 90:1377–1382. doi: 10.1210/jc.2004-1974 CrossRefPubMedGoogle Scholar
  15. 15.
    Schonbrunn A (1999) Somatostatin receptors present knowledge and future directions. Ann Oncol 10(Suppl 2):S17–S21. doi: 10.1023/A:1027392228418 CrossRefPubMedGoogle Scholar
  16. 16.
    Shimon I, Melmed S (1997) Structure and function of somatostatin receptors in growth hormone control. J Endocrinol 155(Suppl 1):S3–S6 (discussion S7–S8)PubMedGoogle Scholar
  17. 17.
    Panetta R, Patel YC (1995) Expression of mRNA for all five human somatostatin receptors (hSSTR1–5) in pituitary tumors. Life Sci 56:333–342. doi: 10.1016/0024-3205(94)00956-2 CrossRefPubMedGoogle Scholar
  18. 18.
    Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:1386–1392. doi: 10.1210/jc.80.4.1386 CrossRefPubMedGoogle Scholar
  19. 19.
    Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724–729. doi: 10.1210/jc.79.3.724 CrossRefPubMedGoogle Scholar
  20. 20.
    Greenman Y, Melmed S (1994) Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398–403. doi: 10.1210/jc.78.2.398 CrossRefPubMedGoogle Scholar
  21. 21.
    Heron I, Thomas F, Dero M, Poutrain JR, Henane S, Catus F, Kuhn JM (1993) Treatment of acromegaly with sustained-release lanreotide, a new somatostatin analog. Presse Med 22:526–531PubMedGoogle Scholar
  22. 22.
    Stewart PM, Kane KF, Stewart SE, Lancranjan I, Sheppard MC (1995) Depot long-acting somatostatin analog (Sandostatin LAR) is an effective treatment for acromegaly. J Clin Endocrinol Metab 80:3267–3272. doi: 10.1210/jc.80.11.3267 CrossRefPubMedGoogle Scholar
  23. 23.
    Attanasio R, Baldelli R, Pivonello R, Grottoli S, Bocca L, Gasco V, Giusti M, Tamburrano G, Colao A, Cozzi R (2003) Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88:5258–5265. doi: 10.1210/jc.2003-030266 CrossRefPubMedGoogle Scholar
  24. 24.
    Ronchi CL, Boschetti M, Degli Uberti EC, Mariotti S, Grottoli S, Loli P, Lombardi G, Tamburrano G, Arvigo M, Angeletti G, Boscani PF, Beck-Peccoz P, Arosio M (2007) Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicenter longitudinal study. Clin Endocrinol (Oxf) 67:512–519Google Scholar
  25. 25.
    Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, Ferretti E, Ferone D, Gaia D, Camanni F, Lombardi G, Tamburrano G (2000) Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 85:4099–4103. doi: 10.1210/jc.85.11.4099 CrossRefPubMedGoogle Scholar
  26. 26.
    Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 90:4465–4473. doi: 10.1210/jc.2005-0260 CrossRefPubMedGoogle Scholar
  27. 27.
    Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 8:2957–2968. doi: 10.1210/jc.2008-0027 CrossRefGoogle Scholar
  28. 28.
    Chanson P, Borson-Chazot F, Kuhn J-M, Blumberg J, Maisonobe P, Delemer B (2008) Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 69:299–305. doi: 10.1111/j.1365-2265.2008.03208.x CrossRefGoogle Scholar
  29. 29.
    Bates AS, Evans AJ, Jones P, Clayton RN (1995) Assessment of GH status in acromegaly using serum growth hormone, serum insulin-like growth factor-1 and urinary growth hormone excretion. Clin Endocrinol (Oxf) 42:417–423. doi: 10.1111/j.1365-2265.1995.tb02651.x CrossRefGoogle Scholar
  30. 30.
    Wass JAH (1997) Growth hormone, insulin-like growth factor-I and its binding proteins in the follow-up of acromegaly. J Endocrinol 155(Suppl 1):S17–S19PubMedGoogle Scholar
  31. 31.
    Freda PU, Post KD, Powell JS, Wardlaw SL (1998) Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly. J Clin Endocrinol Metab 83:3808–3816. doi: 10.1210/jc.83.11.3808 CrossRefPubMedGoogle Scholar
  32. 32.
    Growth Hormone Research Society, Pituitary Society (2004) Biochemical assessment and long-term monitoring in patients with acromegaly: statement from a joint consensus conference of the growth hormone research society and the pituitary society. J Clin Endocrinol Metab 89:3099–3102. doi: 10.1210/jc.2003-031138 CrossRefGoogle Scholar
  33. 33.
    Alexopoulou O, Bex M, Abs R, T’Sjoen G, Velkeniers B, Maiter D (2008) Divergence between growth hormone and insulin-like growth factor-I concentrations in the follow-up of acromegaly. J Clin Endocrinol Metab 93:1324–1330. doi: 10.1210/jc.2007-2104 CrossRefPubMedGoogle Scholar
  34. 34.
    Freda PU (2000) Advances in the diagnosis of acromegaly. Endocrinologist 10:237–244. doi: 10.1097/00019616-200010040-00005 CrossRefGoogle Scholar
  35. 35.
    Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89–95. doi: 10.1530/EJE-08-0267 CrossRefPubMedGoogle Scholar
  36. 36.
    Parkinson C, Ryder WDJ, Trainer PJ (2001) The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab 86:5240–5244. doi: 10.1210/jc.86.11.5240 CrossRefPubMedGoogle Scholar
  37. 37.
    Weissberger AJ, Ho KK, Lazarus L (1991) Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 72:374–381CrossRefPubMedGoogle Scholar
  38. 38.
    Engstrom BE, Burman P, Karlsson FA (2002) Men with acromegaly need higher doses of octreotide than women. Clin Endocrinol (Oxf) 56:73–77. doi: 10.1046/j.0300-0664.2001.01440.x CrossRefGoogle Scholar
  39. 39.
    Colao A, Pivonello R, Cappabianca P, Briganti F, Tortora F, Auriemma RS, De Martino MC, Marzullo P, Lombardi G (2005) Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly. Clin Endocrinol (Oxf) 63:342–349. doi: 10.1111/j.1365-2265.2005.02351.x CrossRefGoogle Scholar
  40. 40.
    Dobrashian RD, O’Halloran DJ, Hunt A, Beardwell CG, Shalet SM (1993) Relationships between insulin-like growth factor-1 levels and growth hormone concentration during diurnal profiles and following oral glucose in acromegaly. Clin Endocrinol (Oxf) 38:589–593. doi: 10.1111/j.1365-2265.1993.tb02139.x CrossRefGoogle Scholar
  41. 41.
    Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91:2112–2118. doi: 10.1210/jc.2005-2110 CrossRefPubMedGoogle Scholar
  42. 42.
    Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, Caron P, Charbonnel B, Cortet C, Delemer B, Escobar-Jimenez F, Foubert L, Gaztambide S, Jockenhoevel F, Kuhn JM, Leclere J, Lorcy Y, Perlemuter L, Prestele H, Roger P, Rohmer V, Santen R, Sassolas G, Scherbaum WA, Schopohl J, Torres E, Varela C, Villamil F, Webb SM (2000) Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf) 53:577–586. doi: 10.1046/j.1365-2265.2000.01134.x CrossRefGoogle Scholar
  43. 43.
    Turner HE, Vadivale A, Keenan J, Wass JA (1999) A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf) 51:275–280. doi: 10.1046/j.1365-2265.1999.00853.x CrossRefGoogle Scholar
  44. 44.
    Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G (1999) A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol 141:267–271. doi: 10.1530/eje.0.1410267 CrossRefPubMedGoogle Scholar
  45. 45.
    van Thiel SW, Romijn JA, Biermasz NR, Ballieux BE, Frolich M, Smit JW, Corssmit EP, Roelfsema F, Pereira AM (2004) Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol 150:489–495. doi: 10.1530/eje.0.1500489 CrossRefPubMedGoogle Scholar
  46. 46.
    Ashwell SG, Bevan JS, Edwards OM, Harris MM, Holmes C, Middleton MA, James RA (2004) The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol 150:473–480. doi: 10.1530/eje.0.1500473 CrossRefPubMedGoogle Scholar
  47. 47.
    Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abstract R, Maiter D (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 151:317–324. doi: 10.1530/eje.0.1510317 CrossRefPubMedGoogle Scholar
  48. 48.
    Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C (2002) Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf) 56:65–71. doi: 10.1046/j.0300-0664.2001.01438.x CrossRefGoogle Scholar
  49. 49.
    Gutt B, Bidlingmaier M, Kretschmar K, Dieterle C, Steffin B, Schopohl J (2005) Four-year follow-up of acromegalic patients treated with the new long-acting formulation of lanreotide (Lanreotide Autogel). Exp Clin Endocrinol Diabetes 113:139–144. doi: 10.1055/s-2005-837520 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Yoel Toledano
    • 1
  • Liat Rot
    • 2
  • Yona Greenman
    • 3
    • 13
  • Sophia Orlovsky
    • 4
  • Yulia Pauker
    • 5
  • David Olchovsky
    • 9
    • 13
  • Achia Eliash
    • 6
  • Orit Bardicef
    • 5
  • Ofa Makhoul
    • 7
  • Gloria Tsvetov
    • 2
    • 13
  • Michal Gershinsky
    • 5
  • Odile Cohen-Ouaqnine
    • 7
  • Rosane Ness-Abramof
    • 10
  • Zaina Adnan
    • 11
  • Jacob Ilany
    • 12
  • Hadassah Guttmann
    • 4
  • Mazal Sapir
    • 8
  • Carlos Benbassat
    • 2
    • 13
  • Ilan Shimon
    • 2
    • 13
  1. 1.Unit of Endocrinology & DiabetesHillel Yaffe Medical CenterHaderaIsrael
  2. 2.Institute of EndocrinologyRabin Medical CenterPetah TiqvaIsrael
  3. 3.Institute of Endocrinology, Metabolism and HypertensionSourasky Medical CenterTel AvivIsrael
  4. 4.Maccabi Health ServicesHaifaIsrael
  5. 5.Clalit Health ServicesHaifaIsrael
  6. 6.Maccabi Health ServicesBnei-BrakIsrael
  7. 7.Clalit Health ServicesJerusalemIsrael
  8. 8.Clalit Health ServicesTel AvivIsrael
  9. 9.Department of Medicine ASheba Medical CenterTel HashomerIsrael
  10. 10.Endocrine UnitSapir Medical CenterKfar SabaIsrael
  11. 11.Institute of Endocrinology, Diabetes and MetabolismRambam Medical CenterHaifaIsrael
  12. 12.Institute of EndocrinologyChaim Sheba Medical CenterTel HashomerIsrael
  13. 13.Sackler Faculty of MedicineTel Aviv UniversityTel AvivIsrael

Personalised recommendations